3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Glioblastoma
8
Breast Neoplasms
7
Prostatic Neoplasms
6
Lung Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Urinary Bladder Neoplasms
5
Glioma
5
Astrocytoma
5
Oropharyngeal Neoplasms
4
Esophageal Neoplasms
4
Carcinoma
4
Burkitt Lymphoma
4
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Rectal Neoplasms
3
Neoplasm Metastasis
3
Adenocarcinoma of Lung
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Pancreatic Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Liposarcoma
2
Laryngeal Neoplasms
2
Hodgkin Disease
2
Gliosarcoma
2
Ganglioneuroblastoma
2
Interventions
Cisplatin
6
Paclitaxel
4
pembrolizumab
3
Fluorouracil
3
Carboplatin
3
tislelizumab
2
Taxes
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Injections
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
lenvatinib
1
durvalumab
1
cixutumumab
1
apatinib
1
Tegafur
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiation
1
Levoleucovorin
1
Laparoscopy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Fulvestrant
1
Docetaxel
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Radiation
×
30 days
×
Clear all
NCT04550260
2026-05-13
KUNLUN
AstraZeneca
Phase 3
Active not recruiting
640 enrolled